Asklepios BioPharmaceutical, Inc. (AskBio)

Asklepios BioPharmaceutical, Inc. (AskBio) is a privately held, clinical stage gene therapy platform company dedicated to improving the lives of children and adults with rare genetic disorders. AskBio’s gene therapy platform includes an industry-leading proprietary cell line manufacturing process known as Pro10™, an extensive AAV capsid library, and synthetic promoter technology. The company has generated hundreds of proprietary third generation gene vectors, several of which have entered clinical testing, and maintains a portfolio of development programs across a range of indications, including Pompe, Limb Girdle Muscular Dystrophy, Cystic Fibrosis, Myotonic Muscular Dystrophy and Huntington’s; other programs that use AskBio’s technology include Hemophilia (Chatham Therapeutics/Takeda) and Duchenne Muscular Dystrophy (Bamboo Therapeutics/Pfizer). For more information, visit www.askbio.com.